Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Banco Santander S.A.

Banco Santander S.A. increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 87,286 shares of the medical research company’s stock after purchasing an additional 10,714 shares during the period. Banco Santander S.A.’s holdings in Thermo Fisher Scientific were worth $43,434,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. IMA Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $35,000. Navigoe LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.1%

Shares of NYSE TMO opened at $462.74 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The firm has a market capitalization of $174.68 billion, a PE ratio of 26.76, a PEG ratio of 2.50 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $420.88 and a two-hundred day moving average price of $467.66.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective on the stock in a research note on Friday, July 11th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research note on Thursday, July 24th. HSBC reiterated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.